Treatment Subgroups (Male) Treatment Subgroups (Female)  
Week AML HCZ AML HCZ Gender Effect
0 160.70 ± 1.42 157.80 ± 1.63 159.70 ± 2.11 162.60 ± 2.46 0.358NS
1 160.40 ± 1.50 157.80 ± 1.57 158.60 ± 2.18 162.20 ± 2.55
3 159.30 ± 1.63 158.40 ± 1.77 157.40 ± 2.37 162.70 ± 2.55
6 157.60 ± 1.68 159.00 ± 1.69 156.10 ± 2.42 162.80 ± 2.56
12 156.60 ± 1.60 159.90 ± 1.62 155.40 ± 2.40 164.60 ± 2.51
24 155.90 ± 1.62 160.40 ± 1.60 153.20 ± 2.36 165.90 ± 2.57
36 155.70 ± 0.44 160.60 ± 1.16 153.0 ± 2.15 166.20 ± 2.64
48 155.30 ± 1.77 160.90 ± 1.66 153.50 ± 2.30 164.70 ± 2.65

Treatment and time-dependent effects on triglycerides are insignificant; other abbreviations are as used in table 2. (N=10 per subgroup)
Table 4: Effects of monotherapy with AML and HCZ on triglycerides (mg/dl) in type 2 diabetic hypertensive subjects for 48 weeks.